Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.

NCT00141180 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00141180
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00141180 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Placebo-Controlled, Randomized, Parallel Group, Multiple-Dose Study to Evaluate the Effects of CP-481,715 on Clinical Response and Cellular Infiltration Following Contact Allergen Challenge to the Skin of Nickel Allergic Subjects.
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2003
Completion date
October 31, 2005
Enrollment
48
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

dermatitis, allergic contact